Welcome to our dedicated page for Ginkgo Bioworks Holdings news (Ticker: DNA), a resource for investors and traders seeking the latest updates and insights on Ginkgo Bioworks Holdings stock.
Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) is pioneering the field of synthetic biology by providing an innovative horizontal platform for cell programming. Specializing in flexible, end-to-end services, the company addresses diverse challenges across multiple sectors including food, agriculture, pharmaceuticals, industrial chemicals, and specialty chemicals. Ginkgo Bioworks is organized into two primary segments: Cell Engineering and Biosecurity, with the latter contributing the majority of the company's revenue through data analytics and related services.
One of Ginkgo Bioworks' recent highlights includes the acquisition of AgBiome's platform assets, significantly enhancing its R&D capabilities in agricultural biotechnology. This move has expanded Ginkgo's proprietary metagenomics database, creating a rich resource for AI model development. Furthermore, the company is actively engaged in partnerships to amplify its technological reach, such as its collaboration with Il Granaio delle Idee to enhance sourdough bakery strains and with GreenLab to produce brazzein, a high-intensity sweetener, on a commercial scale.
Ginkgo Bioworks is also a key player in biosecurity, developing advanced infrastructure and technologies to predict, detect, and respond to biological threats. The company's upcoming Biofab1, a fully integrated lab data center expected to open in mid-2025, is part of its strategic plan to streamline operations and achieve adjusted EBITDA breakeven by the end of 2026.
Additionally, Ginkgo's platform is making significant strides in the AI and data generation space, offering services that help clients leverage high-quality data for more effective R&D. Notably, the company recently hosted its 5th annual Ferment conference, where it showcased new products and technological advancements to a global audience.
Despite facing some financial challenges, including a need to regain compliance with NYSE listing standards due to stock price fluctuations, Ginkgo remains committed to its mission. The company continues to innovate and form strategic partnerships, such as its recent agreement with Sojitz Corporation to penetrate the Japanese market, enhancing its role in the global bioeconomy.
For more information, visit ginkgobioworks.com or follow them on social media platforms like X (@Ginkgo and @Ginkgo_Biosec), Instagram (@GinkgoBioworks), Threads (@GinkgoBioworks), and LinkedIn.
Ginkgo Bioworks reported strong financial results for 2021, with total revenue reaching $314 million, a remarkable 309% increase from 2020. The company added 31 new Cell Programs, representing a 72% growth year-over-year. Despite a $1.8 billion loss from operations, largely due to stock-based compensation adjustments, Ginkgo maintains a strong cash position with over $1.5 billion. For 2022, Ginkgo anticipates total revenue between $325 million and $340 million and expects to add 60 new Cell Programs.
The joint COVID-19 testing program by Concentric by Ginkgo, the CDC, and XpresCheck identified Omicron sublineages BA.2 and BA.3 ahead of other U.S. reports. This traveler-based genomic surveillance program, conducted at major U.S. airports, enrolled international travelers voluntarily from September 2021 to January 2022. The findings suggest that the program effectively monitors variants and can enhance public health responses. Leaders from the CDC and XpresCheck emphasized its importance in detecting variants and supporting a robust biosecurity infrastructure.
Ginkgo Bioworks (NYSE: DNA) announced a presentation and Q&A session on March 28, 2022, to review business performance for the fourth quarter and full year ended December 31, 2021. The session will begin at 4:30 p.m. ET, with details available on their investor relations site. Additionally, the company will hold its annual shareholder meeting on June 10, 2022, allowing participation through a virtual platform for shareholders of record as of April 14, 2022.
Ginkgo Bioworks (NYSE: DNA) has announced its participation in the Jefferies Virtual Synthetic Biology Week, scheduled for March 22, 2022, at 10:00 a.m. Eastern Time. Management will engage in a fireside chat during this event. Details, including a webcast link and a replay, will be available on the company's investor relations website. Ginkgo operates a platform for cell programming, supporting various biotechnology applications across markets like food, agriculture, and pharmaceuticals, while also contributing to COVID-19 response efforts.
Ginkgo Bioworks (NYSE: DNA) has announced a definitive agreement to acquire FGen AG, a Swiss company specializing in strain development and ultra-high-throughput screening technology. This acquisition aims to enhance Ginkgo's cell screening capabilities, allowing exploration of a broader genetic opportunity space. Ginkgo expects that integrating FGen's technology will significantly improve their Design-Build-Test-Learn engine, increasing throughput and efficiency in analyzing millions of genetic prototypes. The transaction is expected to close promptly, with FGen receiving upfront payment and contingent considerations.
Ginkgo Bioworks (NYSE: DNA) announced its participation in notable upcoming conferences, enhancing its visibility in the biotech sector. The events include the Truist Securities AI Symposium on March 1, 2022, Cowen 42nd Annual Health Care Conference on March 8, 2022, featuring a fireside chat and a panel discussion, and the HSBC Build with Bio Conference on March 10, 2022. Interested parties can find more information, webcast links, and presentation replays on the company's investor relations website.
Ginkgo Bioworks (NYSE: DNA) announced its participation in two upcoming conferences. The BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference is scheduled for February 15, 2022, at 10:00 a.m. ET, and the SVB Leerink 11th Annual Global Healthcare Conference will take place on February 18, 2022, at 10:40 a.m. ET. Interested parties can find more details and webcast links on the company's investor relations website.
Ginkgo Bioworks (NYSE: DNA) has acquired Project Beacon COVID-19 LLC, a Boston-based organization focused on enhancing COVID-19 testing accessibility and affordability. This acquisition aims to integrate Project Beacon's assets with Ginkgo's Concentric platform, increasing testing capabilities in Massachusetts and surrounding areas. Ginkgo's Concentric currently serves over 280,000 individuals weekly, having conducted over 3 million tests in the latter half of 2021. The merger is expected to bolster community health initiatives amid rising pandemic concerns.
Ginkgo Bioworks (NYSE: DNA) announced preliminary performance updates for the year ending December 31, 2021. The company expects to meet or exceed its 2021 targets with Biosecurity revenue surpassing its outlook by over 50%. Key highlights include the addition of 30 new cell programs and Foundry revenue exceeding $100 million. Ginkgo reported significant testing volumes through its public health initiative, Concentric, which collected over 280,000 samples weekly. The company will provide audited financial results in March 2022, alongside its outlook for 2022.
Inscripta has announced that Ginkgo Bioworks (NYSE: DNA) has integrated its Onyx™ genome engineering platform into its foundries. This partnership aims to enhance Ginkgo's metabolic and protein engineering workflow efficiency. Initial evaluations indicate that Onyx improved genome editing throughput significantly and reduced design-build-test-learn cycle times by at least 50%. Ginkgo plans to continue investing in innovative technologies that provide faster product development and increased performance in its offerings.
FAQ
What is the current stock price of Ginkgo Bioworks Holdings (DNA)?
What is the market cap of Ginkgo Bioworks Holdings (DNA)?
What does Ginkgo Bioworks do?
What are the main segments of Ginkgo Bioworks?
What recent acquisitions has Ginkgo Bioworks made?
What is Biofab1?
Who are Ginkgo Bioworks' partners?
What is Ginkgo's role in biosecurity?
How is Ginkgo integrating AI in its operations?
What financial challenges is Ginkgo facing?
How can I stay updated with Ginkgo Bioworks' latest news?
When is Ginkgo's next financial update?
